IN8BIO Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, reported its third quarter 2025 financial results and recent business highlights. For the quarter ended September 30, 2025, research and development (R&D) expenses were $2.1 million, down from $3.3 million for the same period in the prior year. This decrease was primarily attributed to a strategic pause in clinical trial-related activities for the INB-400 program and personnel-related costs following pipeline prioritization announced in September 2024. Non-cash items such as stock-based compensation and depreciation accounted for $0.5 million of the R&D expenses. IN8BIO also presented new preclinical data on INB-619, its CD19 targeting gamma-delta T cell engager, at the 2025 American College of Rheumatology $(ACR)$ Convergence Meeting. In preclinical systemic lupus erythematosus models, INB-619 demonstrated complete B cell elimination with potency equivalent to commercial CD19 and CD20 engagers, including FDA-approved blinatumomab and mosunetuzumab, and showed minimal adverse cytokine release. The company expanded its Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University to support faster enrollment and announced that updated clinical data for the INB-200/400 program in newly diagnosed glioblastoma will be presented at the 2025 Society for Neuro-Oncology Annual Meeting. IN8BIO continues to prioritize programs with the strongest clinical signals and commercial opportunities.